Amgen, Inc. (AMGN) Given Average Rating of “Hold” by Analysts
Amgen, Inc. (NASDAQ:AMGN) has been given an average rating of “Hold” by the twenty-five analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $188.85.
A number of analysts have recently issued reports on the company. Bank of America lifted their target price on Amgen to $210.00 and gave the stock a “buy” rating in a research report on Thursday, October 5th. Oppenheimer reaffirmed a “buy” rating and set a $203.00 target price on shares of Amgen in a research report on Friday, October 6th. Mizuho reaffirmed a “buy” rating and set a $198.00 target price on shares of Amgen in a research report on Friday, October 6th. Morgan Stanley reaffirmed an “overweight” rating and set a $196.00 target price (up from $189.00) on shares of Amgen in a research report on Friday, October 6th. Finally, Cann reissued a “buy” rating and issued a $203.00 price objective on shares of Amgen in a report on Friday, October 6th.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total value of $269,665.75. Following the completion of the sale, the executive vice president now directly owns 56,106 shares in the company, valued at $9,921,223.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,050 shares of company stock valued at $1,225,765. Insiders own 0.19% of the company’s stock.
Shares of Amgen (NASDAQ:AMGN) opened at $185.04 on Friday. Amgen has a 52-week low of $150.38 and a 52-week high of $191.10. The stock has a market capitalization of $134,320.00, a PE ratio of 16.72, a PEG ratio of 2.60 and a beta of 1.36. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07.
Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. During the same period in the previous year, the company earned $3.02 earnings per share. The company’s revenue for the quarter was down .7% compared to the same quarter last year. research analysts predict that Amgen will post 12.71 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be given a dividend of $1.32 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a dividend yield of 2.85%. Amgen’s payout ratio is currently 41.55%.
Amgen declared that its Board of Directors has initiated a stock buyback program on Wednesday, October 25th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its stock is undervalued.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related stocks with our FREE daily email newsletter.